Nippon Shinyaku Co., Ltd. (4516)

Name: Nippon Shinyaku Co., Ltd. (4516) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc.

Dati chiave

Capitalizzazione di mercato: JPY 228 billion
Ricavi (esercizio chiuso a 2026-03-31): JPY 170.8B
Utile netto: JPY 29.7B
Margine lordo: 66.4%
Margine netto: 17.4%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	JPY 170.8B	JPY 160.2B	JPY 148.3B	JPY 144.2B
Utile lordo	JPY 113.3B	JPY 109.1B	JPY 98.0B	JPY 88.2B
Risultato Operativo (EBIT)	JPY 35.5B	JPY 35.5B	JPY 33.3B	JPY 30.1B
Reddito netto	JPY 29.7B	JPY 32.6B	JPY 25.9B	JPY 22.8B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4516. /companies/us/4516

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.